Chronic Cavitary and Fibrosing Pulmonary and Pleural Aspergillosis: Case Series, Proposed Nomenclature Change, and Review

David W. Denning,1 Kostantinos Riniotis,1 Richard Dobrashian,2 and Helen Sambatakou1
1School of Medicine, University of Manchester, and 2Department of Radiology, North Manchester General Hospital, Manchester, United Kingdom

We describe 18 nonimmunocompromised patients with chronic pulmonary aspergillosis. Duration of the disease ranged from several months to >12 years. All 18 patients had prior pulmonary disease. Weight loss, chronic cough (often with hemoptysis and shortness of breath), fatigue, and chest pain were the most common symptoms. All 18 patients had cavities, usually multiple and in 1 or both upper lobes of the lung, that expanded over time, with or without intraluminal fungal balls. All had detectable Aspergillus precipitins and inflammatory markers. Elevated levels of total immunoglobulin E were seen in 78% of patients and of Aspergillus-specific immunoglobulin E in 64%. Directed lung biopsies showed chronic inflammation, necrosis, or granulomas without hyphal invasion. Antifungal therapy with itraconazole resulted in 71% of patients improved or stabilized, with relapse common. Interferon-γ treatment was useful in 3 patients. In azole nonresponders, modest responses to intravenous amphotericin B (80%) followed by itraconazole were seen. Surgery removed disease but postoperative pleural aspergillosis was inevitable. Indicators of good long-term medical outcomes were mild symptoms, thin-walled quiescent cavities, residual pleural fibrosis, and normal inflammatory markers.

Aspergillus species cause a wide spectrum of illnesses in humans, including allergy, superficial infection related to local trauma, and invasive disease [1]. The lung is the most frequent site of disease. The host immune system is a major determinant of which particular form of aspergillosis develops, if any. Acute invasive pulmonary aspergillosis (IPA) affects severely immunocompromised persons [2]. Less acute invasive disease (perhaps best termed subacute IPA) has been described, notably in patients with AIDS and chronic granulomatous disease [3, 4]. Aspergilloma is another form of Aspergillus infection that has been well described, in which preexisting pulmonary cavities become colonized by Aspergillus. Aspergillomas have been subdivided into simple and complex according to the radiological appearance [5]. Other chronic forms of Aspergillus infection of the lung that have systemic symptoms have been described. These entities include chronic necrotizing pulmonary aspergillosis (CNPA), semi-invasive aspergillosis, chronic invasive pulmonary aspergillosis, symptomatic pulmonary aspergilloma, and Aspergillus pseudotuberculosis. The distinction between subacute IPA, CNPA, and aspergilloma has not been rigorously defined, and an overlap in clinical and radiological features between these different entities probably exists.

In the course of clinical practice, we have observed patients who have chronic pulmonary disease undoubtedly caused by Aspergillus fumigatus, with clinical features or a course often different from that described in the literature. We have been able to discern 3 distinct radiological patterns of infection. The first is characterized by the formation and expansion of multiple cavities, some containing fungus balls, which we have termed chronic cavitary pulmonary aspergillosis (CCPA). In some cases, this progresses to marked and...
extensive pulmonary fibrosis, which we have termed chronic fibrosing pulmonary aspergillosis (CPA; second category). We have documented pleural involvement in some cases, either as direct invasion of the pleural cavity or as fibrosis. The third category is the progressive enlargement of a single cavity, usually with a thin wall, in some cases to substantial dimensions, occurring slowly over months or rapidly in weeks. This last group of patients probably have slowly progressive invasive aspergillosis, a disease entity similar to or identical to the previously described CNPA. These patients differ slightly from those with CCPA and CFPA because they usually have minor or moderate degrees of immune dysfunction, such as diabetes or corticosteroid use. We suggest that this condition be called subacute IPA. Herein we use the terms “subacute IPA” and “CNPA” interchangeably.

We describe 18 patients with these 3 forms of subacute or chronic pulmonary aspergillosis (CPA). We describe their clinical courses, diagnostic features, serological patterns, and treatment outcomes. We argue the case for these new terms to describe these chronic destructive conditions. We specifically examined cavity size to establish whether it could be used as a radiological criterion for diagnosis (cavity expansion) and assessing therapeutic response (cavity shrinkage). We also propose diagnostic criteria for CPA and response parameters. The distinction between aspergilloma and these other entities is discussed.

PATIENTS AND METHODS

Patients included all of those referred to one of us (D.W.D.) before the year 2000 who fulfilled the criteria below. On the basis of our experience in managing these cases, and contrasting this experience with the literature, the diagnosis of CPA in this series required all of the following 5 features: chronic (duration of >3 months) pulmonary or systemic symptoms with exclusion of other pulmonary pathogens, such as mycobacteria, that could account for disease; no major discernible immunocompromising factors (e.g., AIDS, leukemia, or transplantation) except for patients with CNPA (see below); radiological evidence of a progressive (over months or years) pulmonary lesion with surrounding inflammation, with or without an intracavitary mass; precipitating (IgG) antibody to Aspergillus (Microgen Bioproduct) in serum (A. fumigatus precipitin test result >1:2, or detectable arcs on immunodiffusion); persistently elevated inflammatory markers (C-reactive protein, erythrocyte sedimentation rate, or plasma viscosity).

After careful and extensive review of the data and the literature, all cases described were subclassified into 3 categories, and pleural disease was classified as primary or secondary (to intervention). The criteria for these subclassifications are primarily radiologically and based on observations over time. Several patients appeared to manifest a different form over time, particularly a transition to fibrosis without treatment or to a necrotizing pattern with corticosteroid therapy.

Patients with CNPA (patients 7, 12, and 14) had an identifiable immune defect described in clinical terms, such as diabetes mellitus, corticosteroid use, prior methotrexate or other immunocompromising treatment, or AIDS, and had radiological evidence of expanding cavities, usually with thin walls. The cavity might contain hyphae visible on microscopy, or Aspergillus might be detected in culture, but not usually.

Patients with CCPA (patients 1–6, 8–13, and 15–18) had multiple cavities, usually small initially, with surrounding inflammatory infiltrates and evidence of progression over months or years. Progression was usually characterized by coalescence of cavities to form larger ones, or fibrosis. Hyphae could be found in the cavity, but the wall of the cavity was composed of chronic inflammatory cells and fibrosis, without hyphal invasion.

Patients with CFPA (patients 3, 6, and 8) were a subset; their disease was the end result of either CNPA or, more commonly, CCPA that was untreated. Fibrosis could be limited to one or both upper lobes but also commonly involved the whole hemithorax.

Some patients also had elevated titers of total IgE (level >20 IU/mL) and Aspergillus-specific IgE (fluorescent enzyme immunoassay [RAST]) (>0.35 Ua/mL) (Immunocap; Pharmacia) in serum. Repeated samples of sputum were cultured for fungus. Some patients had undergone a lung biopsy or resection. Percutaneous lung biopsy (under CT or fluoroscopic guidance) and bronchial biopsy samples were cultured and usually examined histologically (if adequate amounts were obtained). Histological evaluation of tissues included routine and silver staining for fungal hyphae, to document tissue invasion, and acid-fast staining, to exclude mycobacterial coinfection. Scans were analyzed both prospectively and retrospectively, and cavity size was determined by measuring the greatest cavity diameter.

Treatment was given according to need, acceptability, tolerance, efficacy, and availability. Serum azole levels were determined by bioassay and doses tailored to the results (aiming for random itraconazole concentrations of ≥5 μg/mL). Intracavitary amphotericin B was given as described elsewhere ([6] and “Treatment of specific noninvasive Aspergillus diseases: Aspergilloma,” available at: www.aspergillus.man.ac.uk/homepagenew/indexhome.html). The MEDLINE database was used for the review of the English-language medical literature.

CASE REPORTS

Patient 2. This 45-year-old smoker with a mild degree of airflow obstruction presented with a right upper-lobe lesion seen on a chest radiograph in December 1991 in Vancouver,
Canada. He underwent a right upper lobectomy because of presumed malignancy. Macroscopic examination of the specimen revealed a 2-cm cavity with necrotic contents associated with local bronchiectasis and thickening of the parietal pleura. Between the cavity and the lung apex was parenchymal fibrosis. The remainder of the lung specimen showed severe emphysema with fibrosis. Microscopically, the cavity was in an area of cystic bronchiectasis with erosion of the mucosa. The cavity contents were purulent and contained a fungus ball without apparent invasion or tissue eosinophilia. A fibrosing (necrotizing) granuloma was seen superior to the cavity. Stains for acid-fast organisms yielded negative results. Cultures of the lung specimen for Mycobacterium tuberculosis yielded negative results, and cultures for fungus were not done. It was thought that he was cured, because the whole lesion was resected.

In June 1992, he presented with hemoptysis. CT of the thorax revealed a cavity measuring 6.24 cm² with surrounding parenchymal infiltration in the area of previous surgery. Investigations for tuberculosis yielded negative results. A bronchoscopy was done, and culture of the bronchial aspirate yielded A. fumigatus. Culture of material obtained by needle aspiration of the cavity yielded A. fumigatus, but findings of histological examination were unremarkable. At this time, his A. fumigatus precipitins test result was 3+, and this fell to 0 after treatment with itraconazole (200 mg b.i.d. for 1 year, July 1992 to July 1993). However, his cough persisted, and no radiological improvement was seen. CT of his thorax (July 1993) confirmed recurrence of disease (the area of the cavity increased to 16 cm², and there was de novo formation of small cavities in the same vicinity with a fluid level). In November 1993, CT revealed an intracavitary fungus ball together with pleural involvement. He was then treated with voriconazole (200 mg b.i.d. for 7 months, November 1993 to May 1994). Response to this was incomplete; culture of sputum continued to yield A. fumigatus, and A. fumigatus precipitins test results were 2+. CT in March 1994 showed persistence of the cavity mass and irregular subpleural consolidation (figure 1). Contrast instilled in the lung cavity descended all the way down to the pleural space on the right, indicating extensive pleural involvement with invasive aspergillosis. He was subsequently treated with iv amphotericin B (0.5–0.7 mg/kg/day), together with granulocyte colony-stimulating factor (G-CSF; 300 µg sc for 6 weeks), and amphotericin B paste (50–70 mg/day), locally administered through a percutaneous catheter into the cavity on a weekly basis, was given for ~1 month. CT in September 1994 showed a slight reduction in cavity size (area, 15 cm²), more pleural involvement (small pneumothorax), and no evidence of fungus ball. The patient’s A. fumigatus precipitins test result was unchanged (2+). With this therapy, his general condition and symptoms improved, as did the radiological findings. The pleural involvement cleared radiographically, and the right upper lobe cavity was unchanged in size (area, 15 cm²). However, culture of sputum continued to yield A. fumigatus, A. fumigatus precipitins test results remained weakly positive, and his IgE level was 238 IU/mL.

In October 1997, the patient recommenced treatment with itraconazole (200 mg b.i.d., reduced to 100 mg b.i.d.). In May 1999, plasma itraconazole concentrations were 11 µg/mL during treatment with this lower dose. Results of culture of sputum became negative, as did A. fumigatus precipitins test results in serum. He remained nearly asymptomatic, continuing to take itraconazole. No appreciable change was seen on chest radiography for 4 years. In mid-2002, chest radiography showed a large thin-walled apical cavity, with some pleural thickening, and no pulmonary inflammatory infiltrates. He stopped therapy with itraconazole in June 2002. He remained healthy until November 2002, when cough, fatigue, and weight loss recurred. His A. fumigatus precipitins test result rose from 1+ to 4+, and levels of inflammatory markers rose. He made a partial improvement over the next 8 weeks in response to itraconazole treatment but remains unwell. A selection of the patient’s chest radiographs and CT scans can be viewed online (“Chronic necrotising invasive pulmonary aspergillosis,” patient RW, in the Image Library section of the Aspergillus Web site, available at: www.aspergillus.man.ac.uk/homepagew/indexhome.html). He was found to be heterozygous for a 54 mutation in mannose-binding protein [7].

The patient had CCPA at the time of his surgery, without...
tissue invasion, and an intraluminal aspergilloma. However, 6 months later, CCPA developed again, manifest as a new cavity in previously uninvolved lung, and a percutaneous biopsy sample was positive for *Aspergillus*. This was a new infection, because chest radiography after surgery documented complete clearance. His initial response to itraconazole was mediocre, and his infection rapidly relapsed after its discontinuation. Likewise, his response to voriconazole was also mediocre. A more favorable response was noted when the patient received treatment with amphotericin B combined with G-CSF. G-CSF was given on theoretical grounds to augment neutrophil function, although there was no evidence in this patient that his function was defective. It is not possible to evaluate its contribution to success in this patient. A proinflammatory cytokine, such as IFN-γ or granulocyte-macrophage colony-stimulating factor (GM-CSF), might also have been considered. This case is also of interest because CCPA progressed over time to form a new adjacent pulmonary cavity and then to involve the pleura. Stability was achieved with long-term antifungal therapy, with relapse after nearly 5 years of itraconazole treatment.

**Patient 8.** A 37-year-old woman from Gujarat, India, had pulmonary tuberculosis in 1986, was successfully treated, but was left with bilateral upper lobe scarring and a cavity in the left upper lobe. In 1989, she visited Mecca (in Saudi Arabia) and experienced smoke inhalation, with some additional damage to her left lung (figure 2). In March 1994, she became ill, with productive cough, dyspnea, and weight loss (figure 3). CT in June 1994 revealed 3 cavities in her left upper lobe, with areas measuring 12.6, 3.6, and 2.4 cm². Fungus balls consistent with aspergillomas were found in the 2 larger cavities. *A. fumigatus* precipitins test results were 2+, her total serum IgE level was 1800 IU/mL, and culture of sputum yielded *A. fumigatus*. Findings on bronchoscopy were unremarkable, but fluid obtained by bronchial lavage yielded *A. fumigatus*. Histological examination of the biopsy sample did not reveal anything abnormal. She decided not to undergo surgery.

In November 1997, her condition deteriorated. She had gross finger clubbing, dyspnea on mild exertion, cough, frequent episodes of mild hemoptysis, and weight loss. A prior chest radiograph showed complete opacification of the left lung, with multiple cavities, at least 2 of which contained fungal balls (figure 4), widespread consolidation, and a pleural effusion. Itraconazole treatment, 200 mg b.i.d., was started, but she had continual hemoptysis, so in February 1998, intracavitary amphotericin B paste was added. She received this for 3 weeks, but the catheter became infected with *Staphylococcus aureus* and had to be removed.

In July 1998, CT identified only 1 cavity in the left lung, measuring 15.3 cm², with no visible evidence of aspergilloma. The whole of the left lung showed extensive fibrosis and consolidation. However, she continued to have hemoptysis, and her plasma viscosity was 203 (normal, <175 centipoise × 100). Intravenous amphotericin B (1 mg/kg) was also given, and a left bronchial artery embolization was done. A percutaneous lung biopsy of the left lower lobe with an 18-gauge needle was done. Histological examination revealed a core of fibrotic lung tissue containing carbon pigment and focal chronic inflam-
result, 3+; C-reactive protein, 70 mg/L (normal, 0.5 mg/L); IgE, 1000 IU/mL; and Aspergillus-specific IgE, 26 Ua/mL. Because her symptoms and weight had only partially improved, amphotericin B was discontinued and itraconazole, 200 mg b.i.d., was recommended. In October 1998, treatment with IFN-γ, 55 μg sc 3 times weekly, was added to itraconazole treatment.

By January 1999, her weight had increased, and the bouts of hemoptysis were less frequent. A. fumigatus precipitins test result was now 2+, and IgE level was 550 IU/mL. Her plasma viscosity, however, remained elevated at 220, as it had been for 18 months. In April, she had another episode of hemoptysis, and a second bronchial embolization was done. In July 1999, her A. fumigatus precipitins test result was 1+, IgE level had declined to 400 IU/mL, and RAST test results had declined to 7 Ua/mL. At this time, she underwent another bronchial artery embolization to control severe hemoptysis. Since then she has gained weight, felt much better, and had no further episodes of hemoptysis. She continued to take itraconazole and IFN-γ until December 1999 and has remained reasonably well under treatment with itraconazole only since then (February 2003). Her course is depicted in figure 5. She was found to be homozygous for a 54 mannose-binding protein mutation [7].

This case is one of the most severe in this series. Over a period of 10 years, the patient’s disease progressed from apical scarring with a small cavity, in 1987, to complete destruction of the whole left lung with replacement by large, fungus-containing cavities and fibrosis (CFPA). Pulmonary damage from smoke inhalation may have contributed to her deteriorating pulmonary function. Itraconazole alone and amphotericin B intravenously alone both made small contributions to the improvement in her condition. Instillation of amphotericin B paste into the cavity was ineffective and complicated by bacterial infection. Most impressive in this case is the response to treatment with a combination of itraconazole and IFN-γ following amphotericin B therapy. Her weight and the serological markers of the disease mirrored clinical improvement. There has been essentially no radiological change.

RESULTS

Clinical, pathological, and radiological data and procedures for 18 patients are summarized in table 1. Of the 18 patients, 16 were white, and 13 were male. The ages ranged from 20 to 77 years, with a median age of 59 years. The duration of disease was variable and not possible to determine accurately for all patients, but the longest duration was in patient 2 (described above), now 12 years.

Predisposing conditions. None of the patients were immunocompromised. All 18 had prior pulmonary disease (table 1). Nine patients had had tuberculosis, in 5 instances due to atypical organisms. Thirteen patients were cigarette smokers, and 3 had previously consumed excessive amounts of alcohol. One patient was heterozygous for α1-antitrypsin deficiency.

Signs and symptoms. Constitutional symptoms were prominent in all patients, with varying degrees of weight loss, malaise, and fatigue (table 1). There were 3 common clinical presentations. The most common was a chronic productive cough, associated with weight loss and shortness of breath. The second was hemoptysis, usually in association with a chronic cough and general ill health. The least common presentation was that of weight loss associated with fatigue, and general ill health, usually with a minor cough. Overall, the most common symptoms were weight loss (17 patients [94%]), cough (14 [78%]), shortness of breath (9 [50%]), hemoptysis (10 [58%]), moderate to severe fatigue and malaise (5 [28%]), chest pain (3 [17%]), substantial sputum production (2 [11%]), and fever (2 [11%]). Wheezing and anorexia were seen in only 1 patient each. Shortness of breath was a common feature, but in many patients this was related to underlying lung disease. Hemoptysis varied from severe to trivial but in no case was fatal. Two patients had episodic fevers due to empyema, chest infections, or exacerbations of bronchiectasis.

Radiological examination. All patients had radiological evidence of a cavitary lesion in the lung (table 1). The commonest site of involvement was the left upper lobe in 9 cases; however, the right upper lobe was involved in 5 cases, and in 3 it was...
bilateral. The left lower lobe was involved in 1 case. In CCPA, the infiltrates were initially ill-defined areas of consolidation that progressed to form well-defined cavities. These cavities often contained intracavitary masses (fungus balls), debris, or fluids. Commonly there were multiple cavities, some large and others small. The size of the cavities was measured on CT where possible. The areas varied from 2 cm² (2nd cavity in patient 2) to 110 cm² (patient 1). Some cavities had thick walls and were adjacent to thickened pleura, but more commonly they were thin-walled without pleural thickening. In those cases in which cavities pre-existed (i.e., in cases of previous tuberculosis or bronchiectasis), in addition to intracavitary fungus ball formation, cavity expansion and paracavitary infiltrates were seen, which often coincided with clinical relapse or deterioration. Cavity expansion correlated well with continuing ill health as a radiological marker of disease progression, with arrest of expansion with successful therapy. However, cavity wall thickness measured on CT (range, 0.2–2 cm) was not a useful marker of disease activity. Relatively rapid expansion of a cavity (few weeks) was most consistent with subacute IPA or CNPA, compared with the much slower expansion seen with CCPA. One remarkable case of cavity expansion (CNPA) over many months is demonstrated in a series of images from patient 14 [8].

Substantial pleural thickening was noted in 3 of 6 patients with intracavitary fungus balls (aspergillomas) and in 6 patients with no evidence of aspergilloma. Extensive pleural thickening of the left lung preceded CCPA in patient 12. Pleural involvement in 1 case resulted in the formation of a bronchopleural fistula.

One patient (patient 10) presented initially with a solitary pulmonary lesion that was suggestive radiologically of malignancy (the side opposite from his prior squamous cell carcinoma). Levels of inflammatory markers were raised, and *A. fumigatus* precipitins were detectable. Results of biopsy were inconclusive, and he responded clinically to itraconazole over 4 months. The mass then expanded, and the patients developed
Table 1. Clinical characteristics, and radiological, serological, and mycological findings of 18 patients with pulmonary aspergillosis.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Age (y)/sex</th>
<th>Underlying pulmonary disease</th>
<th>Categorization of aspergillosis</th>
<th>Signs and symptoms</th>
<th>Radiological findings</th>
<th>Serological findings</th>
<th>Results of culture for Aspergillus</th>
<th>Procedures performed</th>
<th>Histological results from procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>51/M</td>
<td>Ankylosing spondylitis, mild COPD, Mycobacterium malmoense tuberculosis</td>
<td>CCPA</td>
<td>Cough, weight loss</td>
<td>LUL cavities, aspergilloma, pleural thickening</td>
<td>Aspergillus fumigatus precipitins titer rating, 3+; IgE, 20 IU/mL; RAST, positive</td>
<td>Sputum, positive; drain fluid, positive; BAL fluid, positive</td>
<td>LUL resection; bronchoscopy</td>
<td>Chronic inflammation, abscess cavities, caseous material, Langhans giant cells; none</td>
</tr>
<tr>
<td>2</td>
<td>45/M</td>
<td>Emphysema</td>
<td>CCPA + pleural aspergillosis</td>
<td>Cough, weight loss, chest pain, SOB, hemoptysis</td>
<td>RUL cavity, with infiltrates and pleural thickening</td>
<td>A. fumigatus precipitins titer rating, 2+; IgE, 238 IU/mL; RAST ND</td>
<td>Sputum, positive; BAL fluid, positive; lung biopsy, positive</td>
<td>RUL resection; bronchoscopy; lung biopsy</td>
<td>2-cm cavity with local bronchiectasis and intraluminal fungal ball; negative</td>
</tr>
<tr>
<td>3</td>
<td>73/F</td>
<td>Emphysema, M. malmoense tuberculosis</td>
<td>CCPA then CCFA</td>
<td>Cough, weight loss, SOB, hemoptysis</td>
<td>LUL cavity, aspergilloma, infiltrates, pleural thickening</td>
<td>A. fumigatus precipitins titer rating, 3+; IgE, 10 IU/mL; RAST ND</td>
<td>Sputum, positive</td>
<td>Bronchoscopic biopsy</td>
<td>Negative</td>
</tr>
<tr>
<td>4</td>
<td>20/F</td>
<td>Kyphoscoliosis and bronchiectasis</td>
<td>CCPA then pleural aspergillosis</td>
<td>Cough, weight loss, malaise, episodic fever</td>
<td>LLL infiltrates + cavity, pulmonary abscess, pleuritis</td>
<td>A. fumigatus precipitins titer rating, 3+; IgE, 1200 IU/mL; RAST ND</td>
<td>Sputum, positive; pleural fluid, positive</td>
<td>LLL resection thoracoplasty</td>
<td>Chronic inflammation with eosinophils, Aspergillus hyphae in cavity</td>
</tr>
<tr>
<td>5</td>
<td>67/M</td>
<td>Mild COPD</td>
<td>CCPA</td>
<td>Cough, SOB, hemoptysis, weight loss</td>
<td>Infiltrates, consolidation, LUL cavity, pleural thickening</td>
<td>A. fumigatus precipitins titer rating, 1+; IgE, 5000 IU/mL; RAST ND</td>
<td>Sputum, positive</td>
<td>Lung biopsy</td>
<td>Negative</td>
</tr>
<tr>
<td>6</td>
<td>72/F</td>
<td>Mild COPD, tuberculosis</td>
<td>CCPA then CCFA</td>
<td>Hemoptyis, cough, weight loss</td>
<td>LUL cavity, infiltrates, aspergilloma, pleural thickening</td>
<td>A. fumigatus precipitins titer rating, 4+; IgE, 4500 IU/mL; RAST, 8 Ua/mL</td>
<td>Sputum, positive</td>
<td>Lung autopsy biopsies</td>
<td>Chronic inflammation</td>
</tr>
<tr>
<td>7</td>
<td>54/M</td>
<td>Mycobacterium kansasi tuberculosis, COPD during steroid treatment</td>
<td>Subacute IPA/CNPA</td>
<td>Cough, SOB, chest pain, weight loss, hemoptysis</td>
<td>Infiltrates, consolidation, LUL cavities, aspergilloma</td>
<td>A. fumigatus precipitins titer rating, 2+; IgE, 3400 IU/mL; RAST, 32 Ua/mL</td>
<td>Sputum, positive; BAL fluid, negative; sputum cytology, positive</td>
<td>Bronchoscopic biopsy</td>
<td>Granulomas</td>
</tr>
<tr>
<td>8</td>
<td>37/F</td>
<td>Tuberculosis, smoke inhalation</td>
<td>CCPA then CFPA</td>
<td>Cough, SOB, weight loss, hemoptysis</td>
<td>LL cavities, infiltrates, aspergilloma, pleural thickening</td>
<td>A. fumigatus precipitins titer rating, 3+; IgE, 1800 IU/mL; RAST, 26 Ua/mL</td>
<td>Sputum, positive; BAL fluid, positive</td>
<td>Bronchoscopic biopsy; lung biopsy</td>
<td>Negative; carbon pigment and focal chronic inflammation</td>
</tr>
<tr>
<td>9</td>
<td>46/F</td>
<td>R pneumothoraces, pleurodesis</td>
<td>CCPA</td>
<td>Cough, malaise, weight loss, recurrent chest infections, episodic fever</td>
<td>RUL cavity, bronchiectasis, infiltrates</td>
<td>A. fumigatus precipitins titer rating, 3+; IgE, 1 IU/mL; RAST positive</td>
<td>Sputum, positive; BAL fluid, positive</td>
<td>CT lung biopsy; bronchoscopic biopsy</td>
<td>Chronic inflammatory reaction; negative</td>
</tr>
<tr>
<td>Case</td>
<td>Age/Gender</td>
<td>Diagnosis</td>
<td>Symptoms</td>
<td>Findings</td>
<td>Aspergillus Fumigatus Precipitins Titer Rating</td>
<td>IgE</td>
<td>RAST</td>
<td>Complementary Diagnostics</td>
<td>Laboratory Results</td>
</tr>
<tr>
<td>------</td>
<td>------------</td>
<td>-----------</td>
<td>----------</td>
<td>----------</td>
<td>-----------------------------------------------</td>
<td>-----</td>
<td>------</td>
<td>--------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>10</td>
<td>77/M</td>
<td>COPD, squamous cell carcinoma, LUL segmentectomy</td>
<td>Cough, hemoptysis, weight loss, wheezing</td>
<td>Infiltrates, LUL cavity, pleural thickening</td>
<td>1+; IgE, 260 IU/mL; RAST, 5 U/mL</td>
<td>Sputum, positive; BAL fluid, negative; lung biopsy, negative</td>
<td>Negative; chronic inflammation with fibrosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>43/M</td>
<td>Emphysema, tuberculosis</td>
<td>Hemoptysis, weight loss, SOB</td>
<td>LUL cavity, fluid level, infiltrates</td>
<td>2+; IgE, 260 IU/mL; RAST, negative</td>
<td>Sputum, negative; BAL fluid, negative</td>
<td>Bronchoscopic biopsy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>66/M</td>
<td>Pleural thickening, hypertension</td>
<td>SOB, cough, weight loss</td>
<td>LUL cavity, pleural thickening</td>
<td>3+; IgE, 14 IU/mL; RAST, negative</td>
<td>BAL fluid, positive; pleural fluid, positive, autopsy, pneumonectomy, autopsy</td>
<td>Negative; hyphae; cavity with fibrosis, granulomas, fungal ball, negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>70/M</td>
<td>M. malmoense tuberculosis</td>
<td>Weight loss, SOB, sputum production</td>
<td>RUL contraction, pleural thickening, RUL mass, bilateral UL bronchiectasis</td>
<td>1+; IgE, 180 IU/mL; RAST, 2 U/mL</td>
<td>Sputum, negative; lung biopsy, negative</td>
<td>Lung biopsy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>59/M</td>
<td>Asthma, Mycobacterium avium tuberculosis, diabetes</td>
<td>Weight loss, fatigue, sputum production, mild hemoptysis</td>
<td>10-cm thin-walled RUL cavity with fluid, expanding over 2 years from 2 cm, containing aspergiloma</td>
<td>1+; IgE, 300 IU/mL; RAST, 7 U/mL</td>
<td>Sputum, negative; lung aspiration, Staphylococcus aureus</td>
<td>Cavity aspiration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>76/M</td>
<td>Emphysema, multiple bullae, R basal pneumothorax</td>
<td>Weight loss, anorexia, fatigue</td>
<td>Extensive fibrotic shadowing, LUL and RUL, with L apical pleural fibrosis</td>
<td>3+; IgE, 260 IU/mL; RAST, 7 U/mL</td>
<td>Sputum, negative</td>
<td>None</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>59/M</td>
<td>RLL lobectomy for Legionella infection, chronic bronchitis</td>
<td>Severe weight loss, nonproductive cough, SOB</td>
<td>R extensive pulmonary scarring, pleural thickening, caviation R apex</td>
<td>1+; IgE, 600 IU/mL; RAST, 1 U/mL</td>
<td>Sputum, negative; BAL fluid, negative</td>
<td>Bronchoscopy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>59/M</td>
<td>Emphysema, ? pigeon fancier’s lung</td>
<td>Weight loss, dull central chest pain, cough</td>
<td>Fibrotic destruction of both ULs, pleural thickening</td>
<td>1+; IgE, 360 IU/mL; RAST, 1 U/mL</td>
<td>Sputum, negative; BAL fluid, negative</td>
<td>Bronchoscopy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>44/M</td>
<td>Tuberculosis, alcohol abuse</td>
<td>Hemothorax, productive cough, fatigue</td>
<td>Fibrosis both ULs, pleural thickening, bronchiectasis, cavitation</td>
<td>1+; IgE, 17,000 IU/mL; RAST, 900 U/mL</td>
<td>Sputum, negative; lung tissue, negative</td>
<td>Lung biopsy</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE.** BAL, bronchoalveolar lavage; CCPA, chronic cavitary pulmonary aspergillosis; CFPA, chronic fibrosing pulmonary aspergillosis; COPD, chronic obstructive pulmonary disease; F, female; IPA/CNPA, invasive pulmonary aspergillosis/chronic necrotizing pulmonary aspergillosis; L, left; LL, left lung; LLL, left lower lobe; LUL, left upper lobe; M, male; ND, not done; R, right; RAST, Aspergillus-specific IgE fluoroenzyme immunoassay; RLL, right lower lobe; RUL, right upper lobe; SOB, shortness of breath; UL, upper lobe; y, years; ?, possible/uncertain.
superior vena cava obstruction. Additional biopsies showed chronic inflammation, and he died a few weeks after insertion of a stent and radiotherapy; an autopsy was not done. Whether he had had CFPA or a squamous cell carcinoma that evaded 3 directed biopsies is uncertain.

**Serological testing.** All 18 patients had positive results for *A. fumigatus* precipitins. This was required as part of the definition of disease in this series. The titer of antibodies varied over time and, in a very few instances, precipitins test results reverted to negative at some time in the illness. High titer of antibodies were more common in more seriously ill patients, and generally the titer would rise during exacerbations. One patient with otherwise typical features of CFPA was excluded because of negative results of testing for *A. fumigatus* precipitins on 2 occasions. It is possible therefore that some patients with CFPA do not mount an IgG serological response to *A. fumigatus*.

All 18 patients had elevated acute-phase markers (C-reactive protein, plasma viscosity, or erythrocyte sedimentation rate). However, in the same patient, an inflammatory marker could be normal and another raised, so >1 measurement of inflammation is required for full documentation. Rarely did inflammatory markers fall to normal, even with apparently successful therapy.

Elevated levels of total IgE were seen in 14 (78%) of 18 patients, of whom 13 had levels >200 IU/mL and 7 had levels >400 IU/mL (table 1) early in the course. Some patients seen in the early 1990s did not have *Aspergillus*-specific IgE measured, but of the 14 patients who did have it measured early in their course, it was present in 9 (64%). It was present in all those with total IgE levels of >400 IU/mL.

**Histological examination.** The procedures undertaken for diagnostic and therapeutic purposes are shown in table 1. They included examinations of sputum samples, bronchial washings, percutaneous lung or pleural aspirates, and tissue obtained during thoracotomy. Bronchoscopic biopsy samples yielded negative findings in 7 of 8 instances and showed granulomas (but no hyphae) in 1 patient. Percutaneous lung biopsies were done antemortem in 7 cases and showed hyphae in 1 case (patient 12). However these biopsies did yield some histological information in that chronic inflammation and fibrosis was common, and in 1 case (patient 13), plasma cells, eosinophils, and epithelioid giant cells were seen.

Among the 4 patients who had lung resections, the histological appearance of the lung tissue was similar. Hyphae were found in abnormal cavities in all cases and were not seen to invade lung tissue. In each case, hyphae were found in cavities rather than within the lung parenchyma or cavity walls. The pathological findings described above for patient 2 were typical. Localized bronchiectasis with cavity formation, chronic inflammation, and associated fibrosis appears to be the histological hallmark of CCPA. Fibrosis was prominent in CFPA. In addition, some patients had a prominent eosinophilic infiltrate. Granulomas were often seen sparsely distributed and in some cases were the so-called naked granulomas associated with sarcoidosis. The volume of tissue examined may be important, because only in those who underwent surgery were hyphae demonstrated, with 1 exception. In patient 12, who had remarkable expansion of disease during treatment with corticosteroids, small abscesses containing fungal hyphae were seen in the pleura, surrounded by dense fibrosis, without any such appearances in the lung tissue.

**Microbiologic testing.** Culture of sputum yielded positive results for *A. fumigatus* in 10 cases, and in all instances the fungus was the sole pathogen isolated. Positive culture results were infrequent, however, and often occurred months or years after the patient first presented. Cytological examination of sputum revealed *Aspergillus* hyphae in only 1 case. Ten patients underwent bronchoscopy with bronchoalveolar lavage, and in 4 of them, culture of the fluid samples yielded *A. fumigatus*. One bronchoscopic biopsy sample yielded *A. fumigatus*. Lung biopsy samples or fluid obtained by aspiration were cultured for fungus in 5 instances and yielded *A. fumigatus* on 1 occasion (patient 2) and *S. aureus* on another (patient 14). Culture of pleural fluid yielded *A. fumigatus* on the 3 occasions that it was done, usually after surgery for patients with postpneumonectomy or postlobectomy empyema.

**Treatment.** The patients were treated with corticosteroids, amphotericin B, itraconazole, or voriconazole alone or in combination with IFN-γ or G-CSF. The duration of therapy varied from 12 days to >10 years.

One patient (patient 12) progressed from CCPA to CNPA during corticosteroid treatment, and eventually surgical resection was attempted. He developed *Aspergillus* empyema and died some months after surgery. Another patient (patient 7), given corticosteroids and itraconazole in combination for 6 months, had a slight reduction in the size of the cavity but an increase in the amount of material in the cavity and no improvement of systemic features of disease. Two patients who received no therapy for long periods (patients 3 and 8) had CCPA that progressed to CFPA.

All patients took itraconazole at some time during the course of their disease, and all had detectable blood levels of itraconazole that exceeded 5 μg/mL. In 17 instances, itraconazole was given as primary therapy, and 12 (71%) patients had improvement or stabilization in their condition, without need of further therapy (table 2). Three patients developed severe ankle edema; in 2 of them it prevented further therapy. Even though itraconazole treatment failed in 5 patients, all subsequently were treated with itraconazole as maintenance therapy after amphotericin B, and itraconazole seemed to be effective in maintaining improvement (table 2).

Eleven courses of amphotericin B (0.5–1 mg/kg/day iv) were
given to 10 patients. Eight patients had a marked or moderate response to therapy (assessed after discharge from hospital) (table 2). Two patients had no response to amphotericin B treatment and needed immediate institution of alternative therapy. Seven patients had significant toxicity requiring reductions in dosage or curtailing of therapy, even with the substitution of lipoid-based amphotericin B.

In 4 patients, amphotericin B paste was instilled into lung cavities through a flexible pigtail catheter that was left in situ. In 1 patient, amphotericin B instillation was directly into the pleural cavity (simply dispersed in dextrose), by means of a rigid needle and syringe. In 3 cases, local therapy was accompanied by systemic therapy. One patient (patient 8) developed local sepsis due to Staphylococcus aureus, and the catheter was removed. Two of the 3 other patients appeared to benefit in a minor way and 1 not at all. Reduction in the amount of intracavitary material was seen, but was rarely complete.

IFN-γ was given sc as adjunctive therapy to 3 patients, and all showed improvement. Low dosages were used: initially 50 μg 3 times weekly, reduced to dosages as low as 20 μg 3 times weekly if adverse events, such as chills and fever, were severe.

Treatment was evaluated in accordance with clinical, radiological, serological, and microbiological parameters of response. During treatment, improvements were seen in some, but not all, of these parameters. Particularly useful parameters of response were weight gain (early [<8 weeks]), reduction of coughing (early), falling inflammatory markers (middle [≥6 months]), falling IgE (middle), improvement in inflammation surrounding cavities (late [≥1 year]), and eventually a reduction in cavity size and thinning of the wall of the cavity (late). In no patient did the radiological appearance return to normal, but a good outcome in patients with CCPA and CNPA was a stable thin-walled cavity, with little or no pleural thickening (figure 6). Patients with CFPA did not achieve any radiological response. Titers of Aspergillus precipitins usually fell with improvement, but in some cases precipitins were only just detectable at baseline. The most important parameter of response was the patients’ general well-being and energy level. Hemoptysis was not a good guide to progression, because it was intermittent and would often continue despite other improvements or be arrested by embolization without other markers of response.

Attempts were made to stop oral itraconazole therapy, usually after 1–2 years of therapy. Late relapse was common (exemplified by patients 1 and 3) (figures 7–9). Thus, long-term clinical, serological, and radiological follow-up is mandatory. An argument could be made for not discontinuing therapy, but most patients prefer not to be taking medication. The optimal duration of therapy remains to be established.

Surgery. Four patients underwent surgical resection. In 2 cases, this established a previously unsuspected diagnosis (although in case 4, Aspergillus had already been isolated by culture), and in 2 it was a therapeutic procedure. Three of the 4 patients did well initially. The patient who did not (patient 12) received very little antifungal therapy postoperatively, despite spillage of cavity contents into the pleura. It is notable that patient 2 had a recurrence in the lung after resection surgery, and pleural aspergillosis developed postoperatively in the other 3 patients (patients 1, 4, and 12). Surgery was offered at an early stage to patient 8 when she had CCPA, which she declined, but after progression to complete involvement of the left lung over 3 years with CFPA, her condition prohibited surgery.

Eventual outcome. Ten of 16 patients for whom recent follow-up data are available are still alive. One died of an episode of pneumonia (patient 6), 3 of respiratory failure (patients 3, 10, and 11) (figures 7–9), another of superior vena cava obstruction (patient 13), and another of postoperative complications (empyema and chest wall abscess) 6 months after surgery (patient 12). None of the remaining 10 patients are unequivocally cured, and all have variable degrees of disability.

Table 2. Outcomes of treatment in series of 18 patients with pulmonary aspergillosis.

<table>
<thead>
<tr>
<th>Therapy administered</th>
<th>No. of courses of treatment</th>
<th>Stable or improved</th>
<th>Treatment failure due to progression of disease</th>
<th>Toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Itraconazole primary</td>
<td>17</td>
<td>12</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Voriconazole</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Amphotericin B, ivc</td>
<td>11</td>
<td>9</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>Amphotericin B, intracavitary</td>
<td>4</td>
<td>3</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>IFN-γ in addition to itraconazole</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Itraconazole maintenance (after amphotericin B)</td>
<td>6</td>
<td>6</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

* a Clinically significant toxicity resulting in discontinuation of therapy (except skin reactions with voriconazole).
* b Both photosensitivity skin reactions.
* c Any preparation, usually Fungzone, but course could include 2 or 3 preparations during 1 hospitalization.
* d In association with iv amphotericin B in 2 cases and with itraconazole in 1 case.
* e Sepsis due to Staphylococcus aureus.
* f Stable condition during therapy; relapse was usual when therapy was stopped.
Chronic Pulmonary and Pleural Aspergillosis

DISCUSSION

CPA tends to affect middle-aged persons who are mildly or not immunosuppressed, with a predominance of males. It has an indolent progressive course lasting for years. Chronic productive cough and weight loss with mild hemoptysis, dyspnea, and fatigue are the usual presenting symptoms. Pleural fibrosis and Aspergillus empyema appear to complicate some cases of CPA. The combination of characteristic clinical and radiological findings and either serological results positive for Aspergillus or the isolation of Aspergillus from respiratory samples is highly indicative of CPA.

We have attempted to divide CPA into 3 subcategories: subacute IPA or CNPA, CCPA, and CFPA (figure 10). The distinctions among these subcategories are not absolute but reflect the dominant clinical and radiological manifestations. CPA should be distinguished from acute and subacute IPA at one end of the spectrum and from a simple aspergilloma at the other. Acute IPA occurs in highly immunocompromised patients, such as those with profound neutropenia or who have undergone transplantation [2]. Subacute IPA has been associated with diseases such as AIDS [3], chronic granulomatous disease [4], diabetes mellitus [9], and alcoholism [9], and with low-dose corticosteroid therapy [10, 11]. Local extension of disease into the chest wall, brachial plexus, or vertebral column is occasionally seen in subacute IPA [3, 4] but not in CPA, in which local extension involves only the pleura.

We have identified a subtle immune defect (mannose-binding protein polymorphisms) in some of the patients described here [7] and postulate that many of the differing manifestations

Figure 6. Radiological appearance of the chest of patient 7, after ~7 years of maintenance therapy with itraconazole in 2002. The original chest radiograph obtained in 1994, when the diagnosis of chronic pulmonary aspergillosis was made, showed 2 cavities in the left upper lobe, with thick walls and a rounded shadow at base of the largest cavity, consistent with aspergilloma. The largest cavity had an area of 65 cm² on the radiograph. The fluid level on the chest radiograph reproduced here is related to the very small communication between the cavity and the bronchial tree and the recurrent bacterial infection of the cavity. The remarkable change over 8 years is the gradual thinning of the cavity wall and the complete absence, now, of paracavitary infiltrates.

Figure 7. Chest radiograph of patient 3 obtained in June 1999 by means of advanced multibeam equalization radiography technique, showing a large cavity in the left upper zone surrounded by number of smaller cavities inferiorly and some pleural thickening. There is substantial contraction and fibrosis of the left upper lobe but the appearance of the lower left lobe is nearly normal. Shadows of probable previous tuberculosis are seen at the right apex, and the patient has an indwelling intravenous catheter for administration of amphotericin B.
of CPA will be genetically determined. Recent data obtained from mice are consistent with the hypothesis that alterations in surfactant D are important in aspergillosis [12, 13], and the genes encoding mannose-binding protein and surfactant are in proximity on chromosome 10, which could imply linkage of defects. Other genetic polymorphisms, such as those described in transforming growth factor β, may be important in determining tissue response to chronic exposure to Aspergillus. Several of the patients described in this and other series appear to have had structural pulmonary defects, such as bullae, which could have a similar underlying defect, such as defective surfactant. Some of the clinical and radiological features of CPA are also found in chronic pulmonary histoplasmosis [14] and coccidioidomycosis [15, 16], suggesting that host factors may be as important as which fungus is causing chronic infection, given the rather different features of these fungi. Patients with fibrocystic chronic sarcoidosis also develop pulmonary cavities that may develop into CPA, and this common host response could be partly or completely genetically determined.

A remarkable feature of some of these cases of CPA is the slow progression to unilateral pulmonary fibrosis surrounding pulmonary cavities of those untreated with antifungal drugs.
It is likely that what has been termed complex aspergilloma is synonymous with CCPA, although some patients with CCPA do not have aspergillomas within the cavities [5]. There appears to be a spectrum of cavitary pulmonary disease caused by Aspergillus, from a simple, single aspergilloma in a single cavity to CCPA and CFPA. Radiological evolution over time (particularly cavity expansion and new cavity formation) is helpful in making or excluding the diagnosis of CCPA and distinguishing it from a simple aspergilloma. The formation or expansion of \( \geq 1 \) new cavity over time with surrounding inflammation is typical of CCPA. Evidence of progressive pulmonary (as opposed to pleural) fibrosis is typical of CFPA. Usually there is less pleural thickening in CCPA than in aspergilloma, but more pulmonary fibrosis or an enlarging cavity is seen. Many cavities in CCPA do not have fungal balls in them. The presence of the fungal ball may divert attention away from very significant changes in the surrounding lung or pleura.

The histological diagnosis of invasive aspergillosis requires the presence of invasion of lung tissue by fungus of the Aspergillus species [2]. In the 4 cases described here, in which large portions of the lung have been removed, hyphae were visualized, but always within a cavity and not in lung tissue. In immediate proximity to cavities, there is typically chronic inflammation with fibrosis, sometimes with granulomatous inflammation. These features are similar to those classified by Yousem [28] as a granulomatous bronchiectatic cavity. A lung biopsy will also demonstrate chronic inflammation and fibrosis (sometimes with granulomatous features) with or without hyphae present. The major utility of a biopsy in this context is the exclusion of other major conditions, such as carcinoma, lymphoma, or tuberculosis. Granulomas may suggest sarcoidosis or tuberculosis, but these diagnoses should not be made without excluding CPA by serological testing. The absence of hyphae does not exclude the diagnosis of CPA because of the paucity of hyphae in CPA and the sampling error. We suggest that the presence of any hyphae in tissue defines IPA (acute or subacute) and that chronic inflammatory changes, with or without fibrosis, implies CCPA if other diagnostic criteria are met.

Aspergilli are ubiquitous in the environment. At least 100 species are described. The most common species infecting humans are \textit{A. fumigatus}, \textit{Aspergillus flavus}, \textit{Aspergillus niger}, and \textit{Aspergillus terreus} [1]. Other species, such as \textit{Aspergillus clavatus}, are potent allergens. Only \textit{A. fumigatus} was isolated from our patients. Aspergillus species are almost unique among human pathogens in that they are capable of invoking both invasive and allergic disease, at opposite ends of the immune
Th1 immune response to be that the compelling data showing the importance of a strong local defects are sufficient for the disease to be initiated. It may testing in a routine immunology workup, and perhaps only munologic defects exist in patients with CPA (such as mannose-demonstrable in the patients studied here. If generalized im-

AIDS or chronic granulomatous disease. No such defects were described here is the preexisting pulmonary disease. Phagocyte dysfunction appears to be the common denominator of invasive aspergillosis, generally including subacute cases, such as in AIDS or chronic granulomatous disease. No such defects were demonstrable in the patients studied here. If generalized immunologic defects exist in patients with CPA (such as mannosel-binding protein defects), they may not be readily amenable to testing in a routine immunology workup, and perhaps only local defects are sufficient for the disease to be initiated. It may be that the compelling data showing the importance of a strong Th1 immune response to Aspergillus species [30–32] for a good outcome in experimental invasive aspergillosis are important in CPA as well.

Although treatment of CPA with systemic antifungal therapy appears from our data, and that of others, to be beneficial, the assessment of response is difficult to gauge. Weight gain and improved energy levels were the earliest and most definitive indicators of response. Inflammatory markers also improved, but more slowly, and usually remained elevated even during long-term therapy. Although the response to amphotericin B appeared to be slightly better than that to itraconazole, it required long hospitalization periods and carried considerable toxicity. Amphotericin B has minor immunomodulating activity [33, 34]. It is possible that this is the explanation for the apparent response to itraconazole as maintenance therapy after amphotericin B yet lack of success as primary therapy. Itraconazole is slightly inhibitory to immune responses likely to be useful for recovery from CPA [35]. This balance between the importance of the antifungal effect and immunomodulation may be why the addition of IFN-γ was helpful. One study [36] reported good responses to corticosteroid therapy, although the apparent large doses were modulated in many cases by concurrent rifampicin therapy.

Surgery plays a small role in the treatment of CPA because of poor overall lung function in many patients. The first surgical resection to treat aspergilloma dates back to 1943 [37], and in many centers, surgery is regarded as the treatment of choice for symptomatic aspergilloma [38, 39]. This view has been questioned, particularly for patients with so-called “complex” aspergillomas [40–42]. Major postoperative complications, such as respiratory failure, bronchopleural fistulas, resistant air space problems, pleural aspergillosis, and even disseminated disease, can occur [40–42]. For example, in 1 retrospective series, 11 (34%) patients with complex aspergillomas died, compared with 1 (5%) patient with a simple aspergilloma [38]. Postoperative pleural aspergillosis (postpneumonectomy em-pyema) is particularly common [38, 42–44], probably for 2 reasons. First, the pleura is involved in the disease process, as shown in the patients with CCPA presented here. Second, spillage of cavity contents at surgery is common, because surgery is difficult. Three of the 4 patients who underwent surgical excision in this series developed pleural aspergillosis subsequently. Thus, surgery should be reserved for patients with reasonable respiratory reserve and no other treatment options. Surgery may be appropriate for patients with severe hemoptysis if embolization fails. Surgical resection and thoracoplasty as treatments for pleural aspergillosis are prone to many complications and should be avoided, if possible. In addition, many patients have underlying respiratory insufficiency, and removal of a lobe of the lung would leave them unacceptably breathless.

Improvement in the prognosis for patients with CFPA re-

quire improvements in medical therapy. No prospective trials of this entity have been done, although some patients have been included in clinical trials of azole antifungal drugs, and 1 trial specifically addressed this population of patients [45].

Table 3. Proposed enrollment criteria for prospective clinical studies of chronic pulmonary aspergillosis (CPA).

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Chronic pulmonary or systemic symptoms (duration, 3 months) compatible with CPA, including at least 1 of the following symptoms: weight loss, productive cough, or hemoptysis</td>
</tr>
<tr>
<td>2</td>
<td>Cavitary pulmonary lesion with evidence of paracavitary infiltrates, new cavity formation, or expansion of cavity size over time</td>
</tr>
<tr>
<td>3</td>
<td>Either positive result of serum Aspergillus precipitins test or isolation of Aspergillus spp. from pulmonary or pleural cavity</td>
</tr>
<tr>
<td>4</td>
<td>Elevated levels of inflammatory markers (C-reactive protein, plasma viscosity, or erythrocyte sedimentation rate)</td>
</tr>
<tr>
<td>5</td>
<td>Exclusion of other pulmonary pathogens, by results of appropriate cultures and serological tests, that are associated with similar disease presentation, including mycobacteria and endemic fungi (especially Coccidioides immitis and Histoplasma capsulatum)</td>
</tr>
<tr>
<td>6</td>
<td>No overt immunocompromising conditions (e.g., HIV infection, leukemia, and chronic granulomatous disease)</td>
</tr>
</tbody>
</table>

**NOTE.** All criteria must be met to be enrolled; for criterion 3, one or the other condition must be met.
In an effort to facilitate this, we propose enrollment criteria for prospective clinical trials (table 3). Although some patients with CPA may have concurrent infection with Mycobacterium species or other pathogens [45], such patients should not be enrolled into clinical trials because the assessment of response is difficult. With current therapies, response time is measured in weeks and months, and studies should therefore be at least 4–6 months long and possibly as long as 12 months, as shown by the chronicity of disease in this series. Relapse months or years later is also problematic, as it is for coccidioidomycosis, and so these studies will require a considerable time investment. Hemoptysis is not a good guide to therapeutic response, because we have seen good clinical and radiological responses with continuing hemoptysis arrested with vessel embolization.

**Acknowledgments**

We are indebted to colleagues who referred patients, including R. O’Driscoll, J. Miles, S. Hanley, A. Bernstein, P. Phillips, and M. Woodhead. We also acknowledge contributions from R. Bissett and other radiologist colleagues who undertook multiple radiological procedures.

**References**